Algorithm to lab, explore Generative AI’s impact in life sciences

Deloitte IndustryAdvantage™ gives your life sciences company access to our full breadth of thinking, experience, and technology from across Deloitte, including our suite of industry-specific GenAI-enabled accelerators. Our innovative approach can help you manage AI-related risks, foster innovation, enhance processes, deliver valuable insights, and drive competitive advantage. Explore how you can harness the potential of GenAI for life sciences with our blog collection.

How can AI revolutionize the pharmaceutical industry? Discover how Eli Lilly's CTO, Tim Coleman, envisions an AI-ready culture that accelerates drug discovery, enhances clinical trials, and improves patient experiences. What are the 10 steps to foster an innovative, agile, and inclusive environment for AI? Find out now!

Adopting a string-of-pearls approach—integrating multiple GenAI use cases with other AI technologies, data, and digital tools—is important for achieving cost efficiencies and other benefits. This requires appropriate “building blocks” to scale AI and GenAI, including creating an enterprise ambition for AI use and operating structures such as a Center of Excellence. These should be accompanied by new ways of working, governance for responsible and ethical AI use, and proactive communication of an AI value narrative.

While generative artificial intelligence (AI) (gen AI) has much promise, clarity in the regulatory environment can help accelerate the AI journey and adoption across regions. Explore the regulatory environment of AI in six geographical jurisdictions.

Increasing competition and the imperative to adopt new technologies like Generative AI (GenAI) are compelling many life sciences (LS) organizations to harness the power of the cloud more effectively. However, many enterprises are hobbled by issues with modernization, shadow IT, and technical debt. Successfully resolving these challenges involves building a future-ready IT ecosystem.

Curious how GenAI can transform medical writing and potentially save billions in R&D? Discover the power of AI in automating clinical summaries, enhancing efficiency, and assisting regulatory compliance. Dive into our case study on Clinical Study Reports and see how AI agents could streamline the authoring process. Ready to transform your workflow? Read more to find out.

Life sciences companies have an opportunity to unlock $5 billion to $7 billion in value from the use of artificial intelligence. We estimate that nearly 90% of value will be derived from three functional areas: research and development, manufacturing and supply chain, and commercial. Over the past 18 months, GenAI has broadened the breadth of value that AI could deliver.

Discover how Generative AI is transforming life sciences organizations. From automating back-office functions to reimagining supply chains, GenAI is being adopted across various use cases. However, a “string of pearls” strategy, connecting multiple use cases, could revolutionize entire processes, streamlining operations and improving efficiencies. Embracing GenAI could be the key to gaining a competitive edge in the life sciences sector.

Generative AI holds immense potential in disrupting marketing teams across the life sciences. It’s poised to help enable hyper-personalized content at scale and precise measurement of sales effectiveness. To harness its power, marketing leaders should anchor investments in key business issues, manage risks through low-risk use cases, focus on differentiation, and integrate GenAI with other technologies for long-term success.

The advent of Generative AI has the potential to slow growing costs and transform the landscape of clinical development. It will do this by accelerating tasks across the clinical life cycle, bringing a greater share of services back within the four walls of biopharma companies, improving experience for talent and patients alike, and ultimately contributing to more efficacious therapies. Learn about some of the potential outcomes enabled by GenAI that are bringing value across the clinical development life cycle.

What does the Generative AI-enabled future of application development and testing look like? Coding will be democratized, and business context—rather than technical barriers—will be the bottleneck to delivery. Testing new products, features, and designs will be faster, cheaper, and easier, making creativity a better long-term predictor of success. Discover six actions your life sciences company can take in meeting the GenAI moment.

How might Generative AI affect the future of quality management in manufacturing? In broad strokes, quality management will likely be characterized by real-time data analysis, predictive analytics, and automation. And where quality management has been historically reactive, GenAI—alongside traditional AI techniques—will emphasize proactive interventions. However, it’s important to consider these factors as your life sciences organization begins its Generative AI journey.

Have questions about how you can better harness the potential of Generative AI in life sciences? Looking to scale up adoption to help create an industry advantage?

Let’s set up a conversation.